[回到前頁查詢結果 | 重新搜尋]

姓名	傅佑璋(Ywu-Jang Fu) 查詢紙本館藏	電子郵件信箱	E-mail 資料不公開
畢業系所	化學工程與材料工程研究所(Chemical and Materials Engineering)
畢業學位	博士(Ph.D.)	畢業時期	089學年第2學期
論文名稱(中)	聚乳酸(PLA)及乳酸/羥基乙酸共聚合物(PLGA) 於抗癌藥物傳輸系統之研究
論文名稱(英)	The study of polylactide and Polylactide-co-glycolide in the anti-cancer drugs delivery stem
檔案	84341006.pdf 本電子論文使用權限為同意立即開放。 已達開放權限電子全文僅授權使用者為學術研究之目的，進行個人非營利性質之檢索、閱讀、列印。 請遵守中華民國著作權法之相關規定，切勿任意重製、散佈、改作、轉貼、播送，以免觸法。	論文使用權限	同意立即開放
		論文語文/頁數	中文/179
		統計	本論文已被瀏覽 2956 次，被下載 2489 次
摘要(中)	本研究是以聚乳酸(Polylactide)及其共聚物乳酸羥基乙酸(Polylactide-co-glycolide)為高分子基質製備藥物輸送系統，以應用於抗癌藥物之控制釋放，研究利用噴霧乾燥技術製備具有控制釋放特性之微膠囊。研究結果顯示噴霧乾燥技術能製備出粒徑為1~10 mm的微小球(microspheres)，並可由壓縮空氣流率控制其粒徑分佈，藉由最適製備參數調整最高能獲得50 % 的產率。藥物含量的分析結果顯示大部分微膠囊的藥物含量均趨近理論值的藥物含量。參數設計統計法對實驗結果的分析可知微膠囊的性質受噴霧乾燥器進料溫度、聚乳酸濃度以及空氣流率影響最顯著。藥物釋放實驗的結果顯示噴霧乾燥技術所製得的微膠囊能持續藥物的釋放達7天以上。研究並發展水溶性抗癌藥物，5-Fluorouracil (5-FU)以噴物乾燥技術包覆於PLGA基質以應用於控制釋放系統，以二氯甲烷/氯仿/甲醇( 1:1:2 V / V )之混合溶劑可製得近球形具緻密層的微膠囊，結果得知微膠囊平均粒徑約2μm，藥物包覆含量約9%，而LA/GA比對藥物之控制釋放是非常重要的影響因素；經最適製程條件產出之微膠囊有良好之表面形態，包覆效率可達90%以上。並藉由高分子基質之LA/GA比例，討論不同釋放時間藥物之釋放模式，使藥物釋出之擴散路徑長度(藥物釋放速率)呈固定常數值，而符合零次釋放之達成。本研究製得之微膠囊藉由血小板吸附實驗評估PLA及PLGA 基質經製備程序後之生物相容性。並利用人類口腔癌細胞(KB) 與包覆抗癌藥物微膠囊之釋放液進行細胞培養實驗，經MTT比色分析，可証明抗癌藥物的釋放作用確實具有抑制人類口腔癌細胞(KB)增生繁殖，而達到有效的治療效果。
摘要(英)	The purpose of this study is to design the drug delivery system by using polylactide and poly (D, L-lactide-co-golycolide) as a polymeric matrix, and apply the devised to controlling the release of anticancer drugs. Research in this study has developed various drug delivery media by spray drying technique. The controlled release microspheres were prepared by spray drying and investigate several process parameters that can affect the characteristics of microspheres. Normal size distribution with diameters ranging from 1 to 10μm was obtained by spray drying technique. A higher yield of microspheres was recovered depending on polymer solution and process conditions employed. Results show that the yield of microspheres could reach 50% and the experimental drug loading approached to the theoretical drug loading. A factorial design approach was used to optimize conditions to produce microcapsules. The main factors affecting spray drying were found to be the initial temperature, polymer concentration and air flow. The in-vitro release of anticancer drug from microspheres sustained over seven days. Then we describe the water soluble anti-cancer drug, 5-Fluorouracil (5-FU) is encapsulated into biodegradable copoly (dl-lactic/glycolic acid)(PLGA) using spray drying method for the development of long-lasting controlled release systems. The mixture of dichloromethane/chloroform/methanol (1:1:2 v/v) resulted in the modification of morphology, while the physical structure of the microsphere varied from a porous PLGA microsphere to a dense PLGA microsphere. The results show that the average diameter was 2mm and anticancer drug loading of microspheres approached approximately 9 % (w/w). Encapsulation efficiency was reached up 90%，depending on the microsphere best formulation. In addition, the lactide/glycolide ratio of the polymer is an important parameter for controlling the release profile of the entrapped anticancer drug. Finally, the blood compatibility of PLA and PLGA samples were estimated in biocompatibility after prepared process. In use of the method of MTT assay, we could confirm the inhibiting proliferation of KB by the releasing anticancer drug and effective therapy to cancer in vitro.
關鍵字(中)	乳酸/羥基乙酸共聚合物 噴霧乾燥法 微膠囊 抗癌藥物 控制釋放 產率 聚乳酸 藥物傳輸系統	關鍵字(英)	Polylactide-co-glycol polylactide spray drying
論文目次	封面 中文摘要 英文摘要 目錄 圖目錄 表目錄 第一章 緒論 第二章 文獻回顧 2.1 藥物之包覆技術 2.2 包覆材質 2.3 抗癌藥物及其作用機轉 2.4 釋放動力學 第三章 以噴霧乾燥法製備非水溶性抗癌藥物之聚乳酸微膠囊及其藥物釋放特性 3.1 前言 3.2 實驗 3.3 結果與討論 3.4 結論 第四章 以噴霧乾燥法製備水溶性藥物之乳酸/羥基乙酸共聚合物(PLGA)微膠囊及其藥物釋放特性 4.1 前言 4.2 藥品與儀器 4.3 實驗 4.4 結果與討論 4.5 結論 第五章 聚乳酸及其共聚物植入物之製備及釋放特性分析 5.1 前言 5.2 實驗 5.3 結果與討論 5.4 結論 第六章 抗癌藥物載體於生物相容性及癌細胞毒性之評估 6.1 前言 6.2 實驗 6.3 結果與討論 6.4 結論 第七章 總結論 參考文獻 發表文獻
參考文獻	1.Y. W. Chien , Novel Drug Delivery System, Marcel Dekker , Inc. , New York (1982).P. B. Deasy, Microencapsulation and related drug Processes, Marcel Dekker Inc.,New York, 8-13, (1984). 2.H. Simpson and I. McKinlay, Poisoning with slow-release fenfluramine, Brit. Med. J., 4, 462-463, (1975). 3.J. R. Gomez and G. Gomez, Depression in general practices: comparison between thrice daily amitriptyline tablets and a single sustained-release capsules at night, Brit. J. Clin. Pract., 26, 33-34 (1972). 4.T. Tsuruts, Biomedical Application of Polymeric Materials, CRC Press, Boca Raton (1995). 5.H. Simpson and I. McKinley, Poisoning with slow-release fenfluramine, Brit. Med. J., 4, 462-463 (197 5). 6.R. S. Harland, C. Dubernet, J. P. Bennit and N. A. Peppas, A model of dissolution-controlled, diffusional drug release from non-swellable polymeric microspheres, J. Control. Rel., 7, 207-215 (1988). 7.J. R. Gomez and G. Gomez, Depression in general practices: comparison between thrice daily amitriptyline tablets and a single liustained-release capsules at night, Brit. J. Clin. Pract., 26, 33-34 ( 1972). 8.C. Bartlett, Comparison of thioridazine tablets to chlorpromazine spansules in the maintenance care of chronic schizophrenics, Curr. Ther. Res., 13, 100-106 (1971). 9.H. G. Boxenbaum, Physiological and pharmacokinetic factors affecting performance of sustained release dosage forms, Drug Dev. Ind. Pharm., 8, 1-25 (1982). 10.R. Harris and R. G. Regalado, A clinical trial of a sustained-release aspirin rheumatoid arthritis, Ann. Phys. Med., 9, 8-18, (1967). 11.Y. W. Chien, Novel Drug Delivery Systems, Marcel Dekker, Inc., New York, (1982). 12.P. K. Gupta, H. Johnson and C. Allexon, In vitro and in vivo evaluation of polylactic acid microspheres for intramuscular drug delivery, J. Control. Rel., 26, 229-238 (1993). 13.P. Beck, J. Kreuter and I. Fichtner, Influence of PIBCA nanopartlcles and liposomes on the toxicity of the anticancer drug rmfoxantrone, J. Microencapsulation, 10, 101-114 (1993). 14.R. Jalil and J. R. Nixon, J. Microencapsulation, 41, 473-484 (1989). 15.R. Bodmeier and H. Chen, J. Pharm. Pharmacol., 40, 754-757 (1988). 16.Y. Kawashima, I. Niwa, T. Handa, H.Takeuchi, T. Iwamoto, and Y. Itoh, Preparation of prolonged-release spherical micromatrix of ibuprofen with acrylic polymer by the emulsion solvent diffusion method for improving bioavailability, Chem. Pharm. Bull., 37, 425 (1985). 17.El-Helw, Y. El-said and E. Ramadan, Effect of core modification on the release and bioavailability of phenazopyridinehydrochloride from ethylcellulose-walled microcapsules, Acta Pharm. Fennica, 97, 29 (1988). 18.A. Kondo, In: Microcapsule Processing and Technology, J. W. V. Valkenburg (Ed.). Marcel Dekker, New York (1979). 19.M. J. D. Eenink, J. Feijen, J. Olijslager, J. H. M. Albers, J. C. Rieke, P. J. Anderson and S. Wan Kim, eds., Elsevier, Amsterdam, p.225(1987). 20.S.Y. Lin and C.J. Yang, Studies on Microencapsulation, Part I: Effect of Ethylene-vinyl Acetate as a coacervation-inducing Agent on the production and release behavior of chlorpromazine hydrochloride microcapsules and tabletted microcapsules, J. Controlled release,3,221(1986). 21.O.L. Sprockel and W.A. Prapaitrakul, A comparision of microencapsulation by various emulsion techniques, Inter. J. Pharm., 58,123(1990). 22.P. J. Watts, M. C. Davies and C.D Melia, microencapsulation using emulsification/solvent evaporation: An overview of techniques and application,Critical Reviews in Therqpeutic Drug Carrier System, 7,235(1990). 23.C. Bartlett, Comparison of thioridazine tablets to chlorpromazine spansules in the maintenance care of chronic schizophrenics, Curr. Ther. Res., 13, 100-106 (1971). 24.Y. Ogawa, Diffraction and diffuse scattering from materials with microfocussed X-rays, fur: J. Hospital Pham. 2. 120 (1992).H. G. Boxenbaum, Physiological and pharmacokinetic factors affecting performance of sustained release dosage forms, Drug Dev. Ind. Pharm., 8, 1-25, (1982). 25.R. Harris and R. G. Regalado, A clinical trial of a sustained-release aspirin rheumatoid arthritis, Ann. Phys. Med., 9, 8-18, (1967). 26.J. M. Newton, Spray drying and its application to pharmaceuticals, Manuf. Chem. Aerosol News, 33, 33-36, (1966). 27.D. Granderton, Unit Process in Pharmacy, William Heinemann Medical Books, London, 110-113, (1968). 28.K. Masters, Spray Drying Handbook, 3rd ed., George Godwin, London, (1979). 29.J. M. Newton, Spray drying and its application to pharmaceuticals, Manuf. Chem. Aerosol News, 33(4), 33-36 (1966). 30.H. Bechgaard and K. Cadefoged, Gastrointestinal transit time of single-unit tablets, J. Pharm. Pharmacol., 33, 791-792 (1981). 31.D. Milovanoric and J. G. Norin, Microencapsulation of sulfadiaztine with cellulose acetate phthalate, Drug Dev. And Pharm., 12, 1249-1258 (1986). 32.P. K. Gupta, H. Johnson and C. Allexon, In vitro and in vivo evaluation of polylactic acid microspheres for intramuscularly drug delivery, J. Controlled Release, 26, 229-238 (1993). 33.R. Jeyanthi and K. Panduranga, Preparation of gelatin microspheres of blecomycin, Int. J. Pharm., 35, 177-179 (1987). 34.P. Beck, J. Kreuter and I. Fichtner, lnfluence of PIBCA nanopartlcles and liposomes on the toxicity of the anticancer drug rmfoxantrone, J. Microencapsulation, 10, 101-114 (1993). 35.T. Tsuruts, Biomedical Application of Polymeric Materials, CRC Press, Boca Raton (1995). 36.C. E. Lowe, U.S. Patent 2,668,162 (1954). 37.A. K. Schneider, U.S. Patent 2,703,316 (1954). 38.J. Kleine, British Patent 779,291 (1957).H. Fukuzaki, M. Yoshida, M. Asano and M. Kumakura, Eur. Polym. J., 25, 1019 (1989). 39.R. A. Miller, J. M. Brady, D. E. Cutright, J. Biomed. Mat. Res., 11, 711 (1977). 40.H. R. Kricheldorf and A. Serra, Polym. Bull., 14, 497 (1985). 41.E. Lillie and R. C. Schultz, Makromol. Chem., 176, 1901 (1975). 42.A. Schindler and D. Harper, J. Polym. Sci., Polym. Lett. Ed., 14, 729 (1976). 43.R. Jalil, J.R.Nixon, Biodegradable poly (lactic acid) and poly (lactide-co-glycolide) microcapsules: problems associated with preparative techniques and release properties, J. Microencapsulation, 7,297-325 (1990). 44.D.H. Lewis, Controlled release of bioactive agents from lactide/glycolide polymers. In: Chasin M, Langer R. editors. Biodegradable polymers as drug delivery systems. New York: Marcel Dekker, p. 1-41 (1990). 45.T.R. Tice, D.R. Cowsar, Biodegradable controlled-release parenteral systems. Pharm Technol, 11, 26-35 (1984). 46.S. Cohen, M.J. Alonso, R. Langer, Novel approaches to controlled release antigen delivery. Int J. Technol Assessment Health Care 10(1), 121-30 (1994). 47.C. G. Pitt, F. I. Chasalow, Y. M. Hibionada, D. M. Klimas and A. Schindler, J. Appl. Polym. Sci., 26, 3779 (1981). 48.K. J. Zhu, R. W. Hendren, K. Jensen and C. G. Pitt, Macromolecules, 24, 1736 (1991). 49.M. Vert, In Degradable Material (S. A. Baremberg, J. L. Brash, R. Narayan and A. E. Redpath, Eds.), CRC Press, Boca Raton, Florida, 11 (1990). 50.H. R. Kricheldorf and A. Serra, Polym. Bull., 14, 497 (1985). 51.M. S. Reeve, S. P. McCarthy, M. J. Downey and R. A. Gross, Polylactide Stereochemistry：Effect on Enzymatic Degradability, Macromolecules, 27, 825-861 (1994). 52.Y. Doi, K. Kumagai, N, Tanahashi and K. Mukai, in Biodegradable Polymers and Plastics (M. Vert, J. Feijen, A. C. Albertsson, G. Scott and E. Chiellini, Eds.), Royal Society of Chemistry, Cambridge, 139 (1992). 53.S. J. Holland, B. J. Tighe and P. L. Gould, J. Control Release, 8, 155 (1990). 54.T. Tsuruts, Biomedical Application of Polymeric Materials, CRC Press, Boca Raton, (1995). 55.M. Vert, G. Schwarch and J. Coudane, Pure Appl. Chem., A 32(4), 787-796 (1995). 56.A. Anscomb, N. Hira and B. Hunt, Brist. J. Surgery, 57, 917-920 (1970). 57.J. M. Brady, D. E. Cutright, R. A. Miller, G. C. Battistone and E. E. Hunsuck,J. Biomed. Mater., 7, 155-166 (1973). 58.P. Christel, F. Chabot, J. L. Leray, C. Morin and M. Vert, Biodegradable composites for internal fixation. Biomaterials. Wiley, New York, 271-280 (1980). 59.P. H. Craig, J. A. Williams, K. W. Davis, A. D. Magoun, A. J. Levy, S. Bogdansky and J. P. Jones, Surg. Gynecol. Obstet., 141, 1-10 (1975). 60.D. E. Cutright, B. Perez, J. D. Beasley, W. T. Larson and W. Posey, Oral Surg., 37, 142-152 (1974). 61.R. K. Kulkarni, K. C. Pani, C. Nauman and F. Leonard, Arch. Surg., 93, 839-843 (1966). 62.M. Vert, Angew. Makromol Chem., 166/167, 155 (1989). 63.E. E. Schmitt and R. A. Polistina, US Patent 3,463,158 (1969). 64.E. J. Frazza and E. E. Schmitt, J. Biomed. Mater. Res. Symp., 1, 43 (1971). 65.D. L. Hay, N. Cheegini and B. J. Masterson, J. Biomed. Mater. Res., 22, 179 (1988). 66.Y. Ikada, J. Jpn. Soc. Adhesion, 16, 17 (1980) 67..Y. Kimura and H. Kudo, J. Controlled Release, 19,201-217 (1992). 68.B. Baras, M.-A. Benoit and J. Cillard, Parameters influencing the antigen release from spray-dried poly(dl-lactide) microparticles, International Journal of Pharmaceutics, 200, 1, 133-145 (2000). 69.D. L. Wise, G. J. McCormick, G. P. Willet and L. C. Anderson, Life Sci., 19, 867-873 (1976). 70.M. Iguarta, K.M. Hernandez, A. Esquisabel, A.R. Gascon, M.B. Calvo and J.L. Pedraz, Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres, J. Controlled Release, 56,63-73 (1998). 71.R.A. Jani, The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide) (PLGA) devices, Biomaterials, 21, 2475-2490 (2000). 72.G. O. Hofmann, Trauma. Surg., 114, 123-132 (1995). 73.D. C.Scott and G. Hollenbeck, Design and manufacture of a zero-order sustained-release pellet dosage form through non-uniform drug distribution in a diffusion matrix, Pharm. Research, 8, 156 (1991) 74.M. Donbrow and Y. Samuelov, Zero order drug delivery from double-layered porous films release rate profiles from ethylcellulose, hydroxpropyl cellulose and polyethylene glycol mixture, J. Pharm. pharmacol., 32, 463 (1979). 75.T. Higuchi, Mechanism of sustained-action medication: Theoretical analysis of rate of release of solid drugs dispersed in solid matrices, J. Pharm. Sci., 52, 1145 (1963). 76.F. Pavanetto, B. Conti, I. Centa and P. Giunchedi. Solvent evaporation, solvent extraction and spray drying for polylactide microsphere preparation, Int. J. Pharm., 84, 151-159(1992). 77.J. M. Newton, Spray drying and its application to pharmaceuticals, Manuf. Chem. Aerosol News, 33(4), 33-36, (1966). 78.C. Thies, Microencapsulation. Mini answer to major problems. Today's Chemisl at Work. Nov. p. 40-45 (1994). 79.D. W. Belcher, D. A. Smith and E. M. Cook, Spray drying equipment, The Encyclopedia of Chemical Process Equipment (W.J. Mead, ed.), Reinhold, New York, 861-874 (1964). 80.J. M. Newton, Spray drying and its application to pharmaceuticals, Manuf. Chem. Aerosol News, 33(4), 33-36 (1966). 81.H. Seager, U. S. Patent 4,016,254 (1977). 82.D. Ganderton, Unit Process in Pharmacy, William Heinemann Medical Books, London, 110-113 (1968). 83.H. A. Lieberman and A. Rankell, Drying, The Theory and Practice of Industrial Pharmacy, Lea and Febiger, Philadelphia, 22-48 (1970). 84.P. Christel, F. Chabot, J. L. Leray, C. Morin and M. Vert, Biodegradable composites for internal fixation. Biomaterials. Wiley, New York, 271-280 (1980). 85.Y. Doi, K. Kumagai, N, Tanahashi and K. Mukai, in Biodegradable Polymers and Plastics (M. Vert, J. Feijen, A. C. Albertsson, G. Scott and E. Chiellini, Eds.), Royal Society of Chemistry, Cambridge, 139 (1992). 86.Kondo, Microencapsulation by spray-drying process, Microcapsule Processing and Technology, Marcel Dekker, Inc., New York, 154-165 (1979). 87.K. Masters, Spray Drying Handbook, 3rd ed., George Godwin, London, (1979). 88.G. Box W. Hunter and J.S. Hunter, Statistics for experimenters, © 1978 by John Wiley&Sons, Inc. New York, NY.Ch.10,pp.306-345. 89.I. C. Heidelberger, N.K. Chaudhuari, P. Danenberg, el al. Fluorinatedgyrimidines: a new class of tumor inhibitory compounds. Nature, 179, 663-666(1957). 90.N.J. Meropol, P.J. Creaven, N.J. Petrelli, Metstatic colorectal cancer: advances in biochemical modulation and new drug development, Seminar Virology, 22, 509-524(1995). 91.N. Wolmark, H. Rockette and E. Mamounas, Direct in situ reverse transcriptase-linkedpolymerase chain reaction with biotinylated primers for the detection of hepatitis C virus RNA in liver biopsies Journal of Clinical Virology, 17(11), 3553-3559 (1999). 92.S. Kase, S. Kubota, T. Watanabe, M. Furukawa, T. Tanino, H. Ishibiki, K. Teramoto and T. Kitajima, Interferon beta increases antitumor activity of 5-fluorowacil against human colon carcinoma cells in vitro and in vivo, Anticancer Research, 13, 369-374 (1993). 93.J. L. Fischel, P. Formento, M. Berlion, J. Berille, J. Gioanni and J. P. Bizzaril, Sequcnce dependent cytotoxic effects of the combination of a new nitrosourea, fotemustine, with 5-fluorouracil plus folinic acid, Cancer Chemotherapy and Pharmacology, 8, 448-454 (1991). 94.C. Heidelbergcr, N.K. Chaudhuari and P. Danenberg, Fluorinatedpynmidines: a new class of tumor inhibitory compounds. Nature, 179, 663-666 (1957). 95.M. D. Bianco, O.Garcia, R. M. Trigo, J. M. Teijon, Biomaterials, 5-Fluorouracil release from copolymeric hydrogels of itaconic acid monoester: I. Acrylamide-co-monomethyl itaconate, 17(11), 1061-1067(1996). 96.Y. E. Fang, Q. Cheng and X. B. Lu, J. App. Polym. Sci., 68,1751-1758 (1998). 97.T. H. Eldredge, J. K. Staas, J. A. Meulbroek, T, R. Tice, and R, M. Gilley. Biodegradable and biocompatible poly (D, L-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal neurotoxin B toxic which enhances the level of toxin neutralizing antibodies. Infect. Immun., 59, 29-78 (1991). 98.D. H.Cutrigh, Controlled release of bioactive agents from lactide/ glycolide polymers, in Biodegradable Polymers as drug delivery Systems., M. Chasin and R. S. Langer (Eds.), Marcel Dekker, New York, 1-41(1990). 99.B. Renu and B. James, In vitro evaluation of Poly (D, L-lactide-co-glycolide) polymer-based implants containing the α-melanocyte stimulating hormone analog, Melanotan-I, Journal of Controlled Release, 45, 49-55, (1997). 100.C.P.M. Verheyen, J.R. de Wijn, C. A. van Blitterswijk, and K. de Groot, Evaluation of hydroxylapatite/poly (l-lactide) composites: Mechanical behavior, J. of Biomed. Mater. Res., 265, 1277-1296 (1992). 101.T. Nakamura, S. Hitomi, S. Watanabe, Y. Shimizu, K. Jamshidi, S. H. Hyon,and Y. Ikada, Bioabsorption of polylactides with different molecular properties, Journal of Biomedical Materials Research, 23, 1115-1130 (1989). 102.H. Pistner, D. R. Bendix, J. Muhling, J. F. Reuther, Poly (L-lactide): a long-term degradation study in vivo Part III. Analytical characterization, Biomaterial, 14(4), 291-298(1993). 103.E. Allemann, J. C. Lerour, R. Gurny and E. Doelker, In Vitro Extended Release Properties of Drug-Loaded Poly (DL Lactic Acid) Nanoparticles Produced by a Salting-out procedure, Pharmaceutical Research, 10, 12, 1732-1737 (1993). 104.P.L. Ritger and N. A. Peppas, A simple equation for description of solute release I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres cylinders or discs, J. Controll. Rel., 5, 23-26. 105.R. Mulzzarelli, G. Bjagini and C. Rizzoli, Reconstruction of parodontal tissue with chitosan, Biomaterials, 10, 598-603 (1989). 106.J. C. Wauss, J. L. Thompsaon and J. Wagyvary, The binding of micellar lipids to chitosan, Lipids, 18, 714-719 (1983). 107.M. Iguarta, K.M. Hernandez, A. Esquisabel, A.R. Gascon, M.B. Calvo, J. L. Pedraz, Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres, J. Controlled Release, 56,63-73 (1998). 108.H. Bechgaard and K. Cadefoged, Gastrointestinal transit time of single-unit tablets, J. Pharm. Pharmacol., 33, 791-792 (1981). 109.T. Hideo, O. Takashi and K. Masao, Effect of polymer species on microencapsulation by a surface neutralization method, Chem. Pharm. Bull., 40, 729-733 (1992). 110.Kato, Y. Takakura, M. Hashida, T. Kimura and H. Sezaki, Physico Chemical and antitumor characteristics of high molecular weight prodrug of Mitomycin C, Chem. Pharm. Bull., 30, 2951-2957, (1982). 111.Y. Raghunathan, L. Amsel, O. Hinsvark and W. Bryant, Sustained- release drug delivery system 1. Coated ion-exchange resin system for phenylpropanolamine and other drugs, J. Pharm. Sci., 70, 379-384, (1981). 112.S. Nakatsuka and A. L. Andrandy, Permeability of vitamin B-12 in chitosan membrane, effect of blending with poly(vinyl alcohol)/permeability, J. Appl. Polym. Sci., 44, 17-28 (1992). 113.M. N. Taravel and A. Domard, Relation between the physicochermcal characteristics of collagen and its interactions with chitosan, Biomaterials, 14, 930-938, (1993) 114.A. Adrover, M. Ciona and M. Grassi, Analysis of controlled release in disordered structures: a percolation model, J. Membrane Sci., 113, 21-30 (1996). 115.D. C.Merritt, L. Chapman and M. Rabb, Arch. Ophthalmol., 91, 439 (1974). 116.J. B.Herrmann and R. J. Kelly, Polyglycolic acid sutures, Arch. Surg.100, 486-490 (1970). 117.D. Bodmer, T. Kissel and E. Traechslin, Factors influencing the release of peptides and proteins from biodegradable parenteral depot systems. Journal of Controlled Release, 21,129- 138 (1992). 118.R. K. Kulkarni, K. C. Pani, C. Newman, and F. Leonard, Polylactic Acid for Surgical Implants, Walter Reed Army Medical Center, Washington, D.C., 12, 59-68 (1966a). 119.R. K. Kulkarni, K. C. Pani, C. Newman, and F. Leonard, Arch. Surg., 93, 839, (1966b). 120.T. Nakamura, S. Hitomi, S. Watanabe, Y. Shimizu, K. Jamshidi, S. H. Hyon,and Y. Ikada, Bioabsorption of polylactides with different molecular properties, Journal of Biomedical Materials Research, 23, 1115-1130 (1989). 121.C.P.M. Verheyen, J.R. de Wijn, C. A. van Blitterswijk, and K. de Groot, Evaluation of hydroxylapatite/poly (l-lactide) composites: Mechanical behavior, J. of Biomed. Mater. Res., 265, 1277-1296 (1992). 122.B. Renu and B. James., In vitro evaluation of Poly(D,L-lactide-co-glycolide) polymer-based implants containing the α-melanocyte stimulating hormone analog, Melanotan-I, Journal of Controlled Release, 45, 49-55 (1997). 123.T. R. Tice, W. E. Meyers. A. V. Schally and T. W. Reding, Inhibition of rat prostate tumors by controlled release of (D-Trp-6)-LHRH from injectable microcapsules. Proc. Int. Symp. Controlled Release Bioact. Mater., 11, 88-89 (1984). 124.H.L.Rochc, Mannual of Rochc Fluorourcail, Clinical Pharmacokinctics, 16, 215-237 ( 1989). 125.BL. Dahl, L. Tronstad, L. Spanberg, Biological tests of a silicophosphate cement. J Oral Rehabil , 2(3), 249-57(1975). 126.BL. Dahl and L. Tronstad, Biological tests on an experimental glass ionomer (silicopolyacrylate ) cement. J. Oral Rehabil, 3(1), 19-24(1976). 127.T. M. Ko, J. C. Lin and S.L.Cooper, Biomaterials, 14,657 (1993). 128.Y. Liu, D. A. Peterson, H. Kimura and D. Schubert, Mechanism of cellular 2-C4, 5-Dimethylthiazol-2-yl] -2, 5-diphenyl-tetrazolium bromide (MTT) reduction. Journal of Neurochemistry, 69, 581-593 (1997). 129.F. Takeru, H.A. Hun, Y. Hideakira, H. Hidetoshi, H. Y. Soo, H. Hitoshi, Applications of MTT assay to primary cultured rat hepatocytes. Biol. Pharm. Bull., 18(10), 1446-9 (1995).
指導教授	徐新興 (Shin-Shing Shyu)
口試日期	2001-07-06	繳交日期	2001-07-06

[回到前頁查詢結果 | 重新搜尋]